Dr. Ritesh Parajuli, MD
Claim this profileUC Irvine Health/Chao Family Comprehensive Cancer Center
Expert in Breast Cancer
Expert in Breast cancer
19 reported clinical trials
46 drugs studied
Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Affiliated Hospitals
Clinical Trials Ritesh Parajuli, MD is currently running
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
More about Ritesh Parajuli, MD
Clinical Trial Related1 year of experience running clinical trials · Led 19 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Ritesh Parajuli, MD has experience with
- Pembrolizumab
- Paclitaxel
- Tucatinib
- Trastuzumab
- Pertuzumab
- Abemaciclib
Breakdown of trials Ritesh Parajuli, MD has run
Breast Cancer
Breast cancer
Skin Cancer
Head and Neck Cancers
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ritesh Parajuli, MD specialize in?
Ritesh Parajuli, MD focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Ritesh Parajuli, MD currently recruiting for clinical trials?
Yes, Ritesh Parajuli, MD is currently recruiting for 10 clinical trials in Orange California. If you're interested in participating, you should apply.
Are there any treatments that Ritesh Parajuli, MD has studied deeply?
Yes, Ritesh Parajuli, MD has studied treatments such as Pembrolizumab, Paclitaxel, Tucatinib.
What is the best way to schedule an appointment with Ritesh Parajuli, MD?
Apply for one of the trials that Ritesh Parajuli, MD is conducting.
What is the office address of Ritesh Parajuli, MD?
The office of Ritesh Parajuli, MD is located at: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California 92868 United States. This is the address for their practice at the UC Irvine Health/Chao Family Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.